Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | CD2 | P06729 | 1/20 | 0.52 |
| ▸ | CD58 | P19256 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 9/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 9/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 9/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31603772 | 0.73 | SOAT2 (0.51) | SRCCD2CD58 | |
| SCHEMBL30317658 | 0.73 | SOAT2 (0.51) | SRCCD2CD58 | |
| SCHEMBL31603773 | 0.73 | SOAT2 (0.51) | SRCCD2CD58 | |
| SCHEMBL20465923 | 0.71 | SSTR4 (0.63) | SSTR4SSTR2SSTR3SSTR5SSTR1 | |
| SCHEMBL38652044 | 0.71 | HDAC3 (0.50) | SRCMLNR | |
| SCHEMBL30317494 | 0.71 | HDAC3 (0.50) | SRCMLNR | |
| SCHEMBL30426495 | 0.71 | HDAC3 (0.50) | SRCMLNR | |
| SCHEMBL30317633 | 0.71 | HDAC3 (0.50) | SRCMLNR | |
| SCHEMBL29905030 | 0.71 | HDAC3 (0.50) | SRCMLNR | |
| SCHEMBL30317520 | 0.71 | HDAC3 (0.50) | SRCMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |